How the Supply Chain Can Insulate its Risk for the Holiday Season

 

Key Points:

  • Beaird Solutions shares how to beat supply chain issues.
  • Pandemic caused simultaneous spike in demand and drop in supply.
  • The global economy will bounce back one of two ways.

Commentary:

Host Jason Schefferstein discussed the rocky supply chain pandemic trends and its future with President David Beaird of Beaird Solutions.

With the global economy refined to a point of precision, Beaird wasn’t surprised that something like COVID-19 could so severely disrupt the operations and performance across all industries. He explained how the supply chain leverages demand with supply, and during the pandemic, the world saw a simultaneous spike in demand and shut down in an uncertain market.

Today people are seeing the effects of failing to plan early. Because of the shift in supply, manufacturers are now finding out they don’t have essential parts or materials needed to create their product/service. While most companies don’t want to keep a supply of inventory on hand due to balance sheets, Beaird recommends it will likely be the differentiator between competition and which businesses can keep their doors open.

“You have this entire inertia to keep inventories low and to keep profits maximized… then if you don’t have the inventory in place, there’s nothing you can do. And then you’re missing sales,” Beaird said.

So how will the economy bounce back? The world is going to go one of two ways:

  1. When things stabilize, it will go back to the global economy processes and operations that was seen pre-pandemic.
  2. Regional or hemispheric economies will arise and decouple the previous global situation.

However, while option two sounds beneficial for many reasons, like increasing American jobs and creating more American-made products, wealthy business owners will likely have to bring their overseas operations back home. While this will bring more jobs, it will also mean higher labor prices, causing the product price increase.

The question lingering is… will Americans be willing to go for that?

More Stories Like This:

Will Manufacturing “Reshore” To Fix Supply Chain Bottlenecks?

Will Consumers Be Seeing Higher Prices as the Result of the Tightened Supply Chain?

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More